BEAMNEUTRAL

Gross Margin

100.0%

Higher than 100% of Healthcare sector peers

Updated 1078h ago

Sector Performance

100th percentile

BEAM

100.0%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

Beam Therapeutics has a gross margin of 100.0%, meaning it spends nothing on the direct costs of producing its revenue — every dollar of sales is pure profit at that stage.

This is far above the healthcare sector median of 69.4%, placing the company in the 100th percentile among peers. Trend data is not available: the year-over-year change is listed as N/A, and the quarter-over-quarter change is also N/A, so there is no historical pattern to assess. The combination of an extremely high gross margin with no trend history suggests limited insight into whether the metric is sustainable or improving, creating uncertainty rather than a clear opportunity. This metric does not contradict the overall NEUTRAL verdict, as the 100% margin is a strong positive but the lack of trend data prevents it from being a decisive factor.

Frequently Asked Questions

What does the Gross Margin tell investors about BEAM?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does BEAM's Gross Margin compare to its sector?

BEAM's Gross Margin of 100.0% compares to a Healthcare sector median of 68.9%, placing it in the 100th percentile.

Who are BEAM's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%), RMD (62.2%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.